Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Bilateral retinoblastoma is a rare type of eye cancer that affects both eyes, usually in young children. It develops in the retina, the light-sensitive layer at the back of the eye that helps create vision. This condition is typically caused by a genetic mutation that allows tumors to form in both retinas. Early detection and treatment are necessary for preserving sight and preventing the spread of cancer.
read more about bilateral retinoblastoma ...The condition occurs when mutations in the RB1 gene cause uncontrolled growth of retinal cells. These cells form tumors that can affect one or both eyes, though bilateral cases involve both. Because it often begins in infancy, symptoms may appear before a child's first birthday. Genetic inheritance plays a strong role, and children with a family history of the disease are at higher risk.
Parents may first notice a white reflection in the pupil, known as leukocoria, which can appear in photos. Other signs include crossed or misaligned eyes, redness, or swelling. Some children show poor vision or sensitivity to light. These symptoms often lead to an eye exam and imaging tests for confirmation.
Eye doctors perform a detailed retinal exam using special lenses and lights under anesthesia. Imaging tests like ultrasound, MRI, or CT scans may also be used to detect tumors. Genetic testing helps confirm whether the condition is inherited or spontaneous. Early diagnosis supports better treatment planning and long-term outcomes.
Children showing signs of retinoblastoma need immediate evaluation from an eye cancer specialist. Early care is necessary to protect vision and overall health. Regular monitoring helps track how the tumor responds to treatment. Family members might need genetic counseling due to inherited risk. Prompt medical attention leads to the best outcomes.
Yes, bilateral retinoblastoma is often linked to an inherited change in the RB1 gene. Even when there is no known family history, a new mutation can still occur early in development. Genetic testing can help confirm the cause and guide screening for family members. Early diagnosis supports better treatment planning and vision protection.
A common early sign is a white reflection in the pupil, often seen in photos with flash. Some children also develop eyes that look crossed or do not line up well. Redness or swelling can happen, but it is not always present. Any of these signs should prompt an urgent eye exam.
Treatment depends on tumor size, location, and whether vision can be saved. Options can include chemotherapy, laser therapy, cryotherapy, or radiation-based approaches. Doctors also monitor closely to see how tumors respond and adjust the plan as needed. The goal is to protect the child's life first, then preserve as much vision as possible.
Yes, regular follow-up is common because tumors can change during early childhood. Ongoing exams help confirm treatment success and catch new growth early. If the condition is genetic, doctors may also watch for related health risks over time. Families often benefit from genetic counseling and a clear monitoring plan.
1. Retinoblastoma Treatment (PDQ®)–Patient Version. National Cancer Institute. https://www.cancer.gov/types/retinoblastoma/patient/retinoblastoma-treatment-pdq. Accessed January 15, 2026.
2. Retinoblastoma. MedlinePlus Genetics. https://medlineplus.gov/genetics/condition/retinoblastoma/. Accessed January 15, 2026.
3. Retinoblastoma. National Eye Institute. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/retinoblastoma. Accessed January 15, 2026.
4. Retinoblastoma. American Cancer Society. https://www.cancer.org/cancer/types/retinoblastoma.html. Accessed January 15, 2026.
5. Retinoblastoma. St. Jude Children’s Research Hospital. https://www.stjude.org/disease/retinoblastoma.html. Accessed January 15, 2026.
6. RB1 Gene. MedlinePlus Genetics. https://medlineplus.gov/genetics/gene/rb1/. Accessed January 15, 2026.